Modified Rankin Scale (mRS)
Modified Rankin Scale · Also known as: mRS, Rankin Scale, Modified Rankin
The Modified Rankin Scale is a simple 0-6 ordinal measure of global disability or dependency in patients with stroke and other neurological conditions. Originally developed by Rankin in 1957 and modified by van Swieten and colleagues in 1988, it remains the most widely used global disability outcome in stroke clinical trials and clinical practice. Its simplicity, brevity, and strong prognostic association make it the gold standard for acute stroke outcome measurement and is mandated as a primary endpoint in virtually all stroke therapeutic trials.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
mRS is the standard global disability outcome in acute stroke clinical trials—use for any randomized controlled trial testing thrombolytics, thrombectomy, neuroprotective agents, or other acute stroke therapies. It is essential in routine acute stroke care for prognostic communication and discharge planning. It is valuable in longitudinal stroke outcome studies examining long-term disability trajectory. It is used in health services research comparing stroke care pathways (comprehensive stroke centers vs. routine hospitals) and quality improvement initiatives. It provides rapid global assessment in resource-limited settings where detailed functional testing is not available. Less suitable when domain-specific disability information is needed (use stroke-specific QoL or Barthel Index for detailed functional assessment); mRS provides global rating only.
Strengths & limitations
- Simplicity and brevity (single 0-6 rating) enable extremely rapid assessment (2-5 minutes) suitable for busy acute settings
- Robust ordinal scale with clear categorical definitions enables consistent clinician rating with good inter-rater reliability when standardized administration is followed
- Strong prognostic power—mRS at baseline, discharge, and follow-up predicts long-term disability, quality of life, and mortality independent of other factors
- Universal applicability to all neurological conditions affecting disability (stroke, TBI, spinal cord injury, etc.); not disease-specific
- Primary endpoint in virtually all major stroke trials; enables direct comparison and meta-analysis across studies using standardized outcome definition
- Ordinal rather than continuous scale; loss of granularity compared to detailed functional assessments (Barthel Index, modified Rankin detailed)
- Inter-rater reliability variable; depends heavily on clinician training and standardization. Untrained raters show moderate agreement; trained raters show good agreement
- Proxy and self-report mRS often disagree; self-report typically higher (better) than proxy rating by family. Source of rating (patient vs. proxy) must be documented
- Conceptual gaps: mRS does not distinguish patients within each grade (two mRS 3 patients may have vastly different functional capabilities); may miss clinically important transitions
Frequently asked
What is the difference between mRS 2 and mRS 3?
mRS 2 = slight disability, independent for daily living, but some activity limitation. Patient can perform self-care (dressing, grooming, toileting) independently; can ambulate, though gait may be abnormal. mRS 3 = moderate disability, some dependence in activities of daily living. Patient requires assistance for some self-care or mobility but is not bedridden. This is the clinical threshold for 'good outcome' (mRS 0-2) vs. 'poor outcome' (mRS 3-6) in trials.
Can mRS be assessed by phone or proxy interview?
Yes, phone and proxy assessment is feasible and widely used in research (especially for follow-up visits avoiding patient travel). However, agreement with in-person clinician rating is not perfect. Telephone and proxy mRS ratings tend to systematically differ from bedside assessment. In critical trials, in-person assessment is preferred; if phone/proxy is used, this should be documented and sensitivity analyses performed.
Is a low baseline mRS (e.g., mRS 0) in a stroke patient a problem?
Baseline mRS 0-1 (no or minimal pre-stroke disability) is actually prognostically favorable—indicates the patient had excellent pre-stroke function and likely has better stroke outcome potential. The concern is high baseline mRS (indicating pre-stroke disability), which predicts worse overall post-stroke outcome. mRS 0 baseline is not a problem; it's a favorable prognostic sign.
How is mRS used as a dichotomous outcome in trials?
mRS is converted to dichotomous outcome: mRS 0-2 (good outcome, independent) vs. mRS 3-6 (poor outcome, dependent). Proportions achieving mRS 0-2 are compared between treatment and control groups at 90 days (primary timepoint). Example: 40% of treatment group achieves mRS 0-2 vs. 26% of control group = statistically significant treatment benefit. This dichotomy is the standard trial primary outcome definition.
Sources
- van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988). Interobserver agreement for the assessment of handicap in stroke patients. Stroke, 19(5), 604-607. DOI: 10.1161/01.STR.19.5.604 ↗
How to cite this page
ScholarGate. (2026, June 3). Modified Rankin Scale. ScholarGate. https://scholargate.app/en/neurology/modified-rankin-scale
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
Compare side by side →